Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Pulmonx (LUNG) EBIT (2019 - 2025)

Pulmonx has reported EBIT over the past 7 years, most recently at -$14.4 million for Q3 2025.

  • Quarterly EBIT fell 1.87% to -$14.4 million in Q3 2025 from the year-ago period, while the trailing twelve-month figure was -$57.2 million through Sep 2025, up 1.77% year-over-year, with the annual reading at -$57.7 million for FY2024, 6.83% up from the prior year.
  • EBIT was -$14.4 million for Q3 2025 at Pulmonx, up from -$14.8 million in the prior quarter.
  • Over five years, EBIT peaked at -$9.8 million in Q3 2021 and troughed at -$16.4 million in Q2 2023.
  • The 5-year median for EBIT is -$14.4 million (2022), against an average of -$14.2 million.
  • Year-over-year, EBIT plummeted 104.69% in 2021 and then increased 11.37% in 2024.
  • A 5-year view of EBIT shows it stood at -$12.4 million in 2021, then dropped by 18.28% to -$14.6 million in 2022, then grew by 4.84% to -$13.9 million in 2023, then rose by 3.61% to -$13.4 million in 2024, then fell by 7.27% to -$14.4 million in 2025.
  • Per Business Quant, the three most recent readings for LUNG's EBIT are -$14.4 million (Q3 2025), -$14.8 million (Q2 2025), and -$14.6 million (Q1 2025).